Melflufen dosage regimens for cancer
AssigneeOncopeptides Innovation AB
InventorJakob LINDBERG
Life of this patent
Estimating the term…
Abstract
The present invention providesmelflufen (melphalan flufenamide; L-Melphalanyl-4-fluoro-L-phenylalanine ethyl ester), or a salt thereof, for use in the treatment or prophylaxis of multiple myeloma, wherein a dosage of melflufen (excluding the mass of any salt) is administered as a parenteral dosage at an infusion rate of 1.0 to 1.8 mg/min. Also provided is melflufen, or a salt thereof, for use in the treatment or prophylaxis of a cancer, for example a solid cancer, wherein a dosage of melflufen is administered as a parenteral dosage at an infusion rate less than 0.8 mg/min (for example 0.3 to 1.0 mg/minor for example 0.3 to 0.8 mg/min).
Claims22
1-21. (canceled)
A method for treating a patient having multiple myeloma comprising administering to the patient on day 1 of a 28-day cycle (a) a 37.5 mg to 42.5 mg parenteral dosage of melflufen at an infusion rate of 1.2 mg to 1.4 mg of melflufen per minute or (b) a parenteral dosage of a melflufen salt in an amount of 37.5 mg to 42.5 mg of melflufen at an infusion rate of 1.2 mg to 1.4 mg of melflufen per minute;
- wherein the cycle is repeated one or more times.
23-27. (canceled)
Dependencies are inferred from the claim text.